Alfacell Corporation says that new findings for the treatment of unresectable malignant mesothelioma were presented on Sunday, October 22 at the 8th International Conference of the International Mesothelioma Interest Group. The post-hoc analysis found that patients treated with Onconase had greater median survival times than patients treated with doxorubicin alone.

Discover The Truth About Cancer That Your Doctor Doesn’t Know And The Drug Companies Hope You Never Find Out. DETAILS HERE